Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early lung cancer test gains R&D (research and development) grant:

This article was originally published in Clinica

Executive Summary

Canada's DiagnoCure and Israel's Compugen have received a cash boost to support their joint project to develop a nucleic acid probe-based diagnostic kit for the early detection of lung cancer. The Canada-Israel Industrial Research and Development Foundation, which promotes collaborative R&D between firms in both countries, has awarded the firms Can $800,000 ($502,000). The lung cancer test will combine Tel Aviv-based Compugen's capabilities in identifying novel disease markers and predicting their utility with Quebec City based DiagnoCure's expertise in developing, manufacturing and commercialising molecular diagnostic assays. Lung cancer is the leading cause of cancer death worldwide, says DiagnoCure. About 1.3 million cases of lung cancer are diagnosed each year. In the US alone, it is estimated that more than 170,000 individuals were diagnosed with lung cancer and 158,000 died from the disease in 2001.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts